Schizophrenia Clinical Trials in New York
View 43 new treatments for Schizophrenia in New York, NY. Every day, Power helps hundreds of Schizophrenia patients connect with leading medical research.Filter Results
Condition
All
How old are you?
Trial Phase
All
Trial Status
All
Emraclidine for Schizophrenia
Cerevel Clinic, New York + 5 more
This trial aims to evaluate the safety and tolerability of a medication called emraclidine, taken by mouth, in adults with schizophrenia.
Verified
Recruiting
No Placebo Trial
Phase 2
Est. 5 - 8 Weeks
Erica Koenig, PhD
Study Director
RL-007 for Cognitive Impairment in Schizophrenia
Recognify Life Sciences Clinic, Cedarhurst + 5 more
This trial is testing a new drug, RL-007, to see if it can help people with schizophrenia think and remember better. The study will compare different doses of the drug and check for any side effects. Participants will take the drug for several weeks and complete memory and thinking tests before and after the treatment.Show More
Verified
Recruiting
Phase 2
Est. 3 - 6 Weeks
Gary Walker, PhD
Study Director
Vortioxetine for Schizophrenia
Research Clinic, Glen Oaks + 1 more
This is a 16-week, randomized, double-blind, parallel group, placebo-controlled study comparing adjunctive vortioxetine with identically appearing adjunctive placebo pills in 88 stable patients with a research diagnosis of schizophrenia determined with the Structured Clinical Interview for DSM (SCID). Patient randomization will be stratified by illness duration (i.e., \</=5 years and \>5 years) in order to allow for post-hoc analyses examining whether earlier illness moderates greater negative and /or cognitive symptom reduction in response to vortioxetine.Show More
Waitlist
Phase 4
Est. 5 - 8 Weeks
Christoph U Correll, MD
Principal Investigator
Clozapine for Schizophrenia
Research Clinic, New York + 3 more
This trial is testing whether clozapine can reduce violent behavior more effectively than usual treatments in adults with schizophrenia who have recently been violent. Clozapine helps by balancing brain chemicals to manage symptoms. The study will last for several months and include regular medical check-ups. Clozapine has been shown to reduce violent and aggressive behavior in patients with schizophrenia, especially those who are treatment-resistant.Show More
Recruiting
No Placebo Trial
Phase 4
Est. 6 - 12 Weeks
Ragy Girgis, MD
Principal Investigator
KarXT for Schizophrenia
Karuna Clinic, Staten Island + 2 more
This trial tests KarXT, a combination of two drugs, for people who haven't improved with their current treatment. KarXT aims to balance brain functions and reduce side effects. The study will look at improvements in health and daily life. KarXT has shown positive results in earlier tests.Show More
Recruiting
Phase 3
Est. 5 - 8 Weeks
Ronald Marcus, MD
Study Director
Cariprazine for Adolescent Schizophrenia
Allergan Clinic, New York + 1 more
The purpose of this study is to evaluate the efficacy and safety of cariprazine in the treatment of schizophrenia in the adolescent population.
Recruiting
Phase 3
Est. 3 - 6 Weeks
Paul Yeung
Study Director
Long-term Safety of Iclepertin for Schizophrenia
Boehringer Ingelheim Clinic, New York + 3 more
This study is open to adults with schizophrenia who took part in a previous CONNEX study (study 1346-0011, 1346-0012, or 1346-0013). The purpose of this study is to find out how well people with schizophrenia can tolerate a medicine called Iclepertin in the long term. Participants take Iclepertin as tablets once a day for 1 year. In addition, all participants take their normal medication for schizophrenia. Participants are in the study for a little more than 1 year. During this time, they visit the study site about 13 times and get about 9 phone calls from the study team. The doctors collect information on any health problems of the participants. Doctors also regularly check the participants' symptoms of schizophrenia.Show More
Recruiting
No Placebo Trial
Phase 3
Est. 3 - 12 Weeks
Unregistered Study Lead
Research Team
KarXT for Schizophrenia
Karuna Clinic, Staten Island + 8 more
This trial tests the safety and tolerability of KarXT, a combination of two drugs, in schizophrenia patients who haven't responded well to their current treatments. KarXT aims to improve symptoms and manage side effects better than existing medications. KarXT (xanomeline plus trospium) is an emerging treatment for schizophrenia, showing promise in managing total, positive, and negative symptoms.Show More
Recruiting
No Placebo Trial
Phase 3
Est. 3 - 12 Weeks
Bristol-Myers Squibb
Study Director
Iclepertin for Schizophrenia
Boehringer Ingelheim Clinic, Staten Island + 1 more
This trial tests if a medicine called Iclepertin can help improve memory and learning in adults with schizophrenia. Participants take Iclepertin daily while continuing their usual medication. Doctors regularly check their mental abilities and health throughout the study. Iclepertin is being studied for its potential to improve cognitive functions in schizophrenia.Show More
Recruiting
Phase 3
Est. 5 - 8 Weeks
Unregistered Study Lead
Research Team
Valbenazine for Schizophrenia
Neurocrine Clinic, New York + 3 more
The primary objective for this study is to evaluate the effect of adjunctive valbenazine versus placebo on symptoms of schizophrenia in participants who have inadequate response to antipsychotic treatment.Show More
Recruiting
Phase 3
Est. 3 - 12 Weeks
Clinical Development Lead
Study Director
Page 1 of 4
Frequently Asked Questions
Explore related conditions